This article provides a wealth of practical information for the individual considering CBD as an adjunctive or alternative treatment for pain and or anxiety. CBD works in the body by manipulating receptors throughout organ tissues, the immune system, the pain response system, the hormonal system, and other systemic regulatory systems. While CBD oils have not been reviewed or approved by the FDA for the treatment of these conditions, a wealth of literature, both anecdotal and research-related now exists to help describe both their safety and effectiveness. As discussed in this article, the potential new adopter must be mindful of several important items. First, only those products that are sourced from Industrial Hemp will be considered legal in all states. One must be careful if the product you choose is sourced from the marijuana plant, as those products may contain THC levels above the legal limit in your given state. Secondly, all products are NOT created equal – they differ significantly in strength, absorption, and elimination by the body and in the manner in which they are formulated. One should be mindful of the differences in doses available for each of these products, starting at a low or moderate dose and increasing as needed in order to find the lowest dose that provides the desired relief. In this way, one can individualize usage to maximize effectiveness, while minimizing risk, a proper goal for the use of all medicinals.
CBD oil may help you quit a problematic addiction. One of the most exciting new areas of research related to CBD is its potential for helping with addiction. CBD has been proposed as a way to help people who are addicted to tobacco or even who are addicted to cannabis—a much rarer problem than tobacco addiction, but nevertheless a major issue for some people.

Your product is not generally recognized as safe and effective for the referenced uses and, therefore, the product is a “new drug” under section 201(p) of the Act [21 U.S.C. § 321(p)]. New drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from the FDA, as described in section 505(a) of the Act [21 U.S.C. § 355(a)]; see also section 301(d) of the Act [21 U.S.C. § 331(d)]. FDA approves a new drug on the basis of scientific data submitted by a drug sponsor to demonstrate that the drug is safe and effective.
×